ChemoCentryx, Inc. (NASDAQ:CCXI) has a beta value of 1.37 and has seen 7,751,827 shares traded in the recent trading session. The company, currently valued at $1.76 Billion, closed the recent trade at $26.74 per share which meant it lost -$22.08 on the day or -45.23% during that session. The CCXI stock price is -162.87% off its 52-week high price of $70.29 and 8% above the 52-week low of $24.6. If we look at the company’s 10-day average daily trading volume, we find that it stood at 682.23 Million shares traded. The 3-month trading volume is 495.39 Million shares.
The consensus among analysts is that ChemoCentryx, Inc. (CCXI) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.54.
ChemoCentryx, Inc. (NASDAQ:CCXI) trade information
Despite being -45.23% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Apr 30 when the CCXI stock price touched $49.60- or saw a rise of 46.63%. Year-to-date, ChemoCentryx, Inc. shares have moved -57.25%, while the 5-day performance has seen it change -42.41%. Over the past 30 days, the shares of ChemoCentryx, Inc. (NASDAQ:CCXI) have changed -47.98%. Short interest in the company has seen 3.56 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $87.25, which means that the shares’ value could jump 226.29% from the levels at last check today. The projected low price target is $57 while the price target rests at a high of $120. In that case, then, we find that the latest price level in today’s session is +348.77% off the targeted high while a plunge would see the stock lose 113.16% from the levels at last check today.
ChemoCentryx, Inc. (CCXI) estimates and forecasts
Figures show that ChemoCentryx, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -1.41% over the past 6 months, with this year growth rate of -110.71%, compared to 16.6% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -286.2% and -31.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -18.4%.
8 analysts offering their estimates for the company have set an average revenue estimate of $4.44 Million for the current quarter. 8 have an estimated revenue figure of $14.55 Million for the next quarter concluding in September 01, 2021. Year-ago sales stood $49.44 Million and $5.08 Million respectively for this quarter and the next, and analysts expect sales will grow by -91% for the current quarter and 186.1% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +4.8% over the past 5 years. Earnings growth for 2021 is a modest +13.6%.
ChemoCentryx, Inc. (NASDAQ:CCXI)’s Major holders
Insiders own 23.65% of the company shares, while shares held by institutions stand at 81.75% with a share float percentage of 107.08%. Investors are also buoyed by the number of investors in a company, with ChemoCentryx, Inc. having a total of 276 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 10.38 Million shares worth more than $642.81 Million. As of December 30, 2020, FMR, LLC held 14.89% of shares outstanding.
The other major institutional holder is Wellington Management Group, LLP, with the holding of over 6.15 Million shares as of December 30, 2020. The firm’s total holdings are worth over $380.73 Million and represent 8.82% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Hartford Mid Cap Fund. As of February 27, 2021, the former fund manager holds about 4.44% shares in the company for having 3097219 shares of worth $210.12 Million while later fund manager owns 2.66 Million shares of worth $151.61 Million as of January 30, 2021, which makes it owner of about 3.81% of company’s outstanding stock.